The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1465-1472

  Chen, Yan ^a   Sun, Jing ^b   Zhao, Hua ^a   Zhu, Dongming ^a   Zhi, Qiaoming ^a   Song, Shiduo ^a   Zhang, Lifeng ^a   He, Songbing ^a   Kuang, Yuting ^a   Zhang, Zixiang ^a   Li, Dechun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

B7 H1; B7 H3; B7 H4; Pancreatic cancer; Tumor infiltrated T cell

Indexed keywords

B7 ANTIGEN; B7 H3 MOLECULE; B7 H4 MOLECULE; B7 HI MOLECULE; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; PANCREAS CANCER; POSTOPERATIVE PERIOD; SURVIVAL RATE; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

EID: 84907307478     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S66809     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71-96.
2. Kleeff J, Michalski C, Friess H, Büchler MW. Pancreatic cancer: from bench to5-year survival. Pancreas.2006;33:111-118.
3. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Büchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg.2004;91: 586-594.
4. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother.2006;29:233-240.
5. Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer: science driving clinical progress. Nat Rev Cancer.2005;5:459-467.
6. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol.2008;8:467-477.
7. Geng L, Huang D, Liu J, et al. B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol.2008;134:1021-1027.
8. Crispen PL, Sheinin Y, Roth TJ, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res.2008;14:5150-5157.
9. Salceda S, Tang T, Kmet M, et al. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res.2005;306:128-141.
10. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med.1999;5:1365-1369.
11. Carter L, Fouser LA, Jussif J, et al. PD-1:PD-L inhibitory pathway affects both CD4+and CD8+T cells and is overcome by IL-2. Eur J Immunol.2002;32:634-643.
12. Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med.2006;203:883-895.
13. Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-γ production. Nat Immunol.2001;2: 269-274.
14. Sun M, Richards S, Prasad DV, Mai XM, Rudensky A, Dong C. Characterization of mouse and human B7-H3 genes. J Immunol. 2002;168:6294-6297.
15. Prasad DV, Richards S, Mai XM, Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity. 2003;18:863-873.
16. Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol Med.2008;14: 550-559.
17. Edge S, editor. AJCC Cancer Staging Manual.6th ed. New York: Springer;2002.
18. Sun J, Xu KF, Wu CP, et al. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens.2007;69: 19-27.
19. Sun J, Chen LJ, Zhang GB, et al. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother.2010;59:1163-1171.
20. Chen LJ, Sun J, Wu HY, et al. B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother.2011;60: 1047-1055.
21. Callahan MK, Wolchok JD. At the bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol.2013;94:41-53.
22. Yamato I, Sho M, Nomi T, et al. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer.2009;101:1709-1716.
23. Sun Y, Wang Y, Zhao J, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer.2006;53:143-151.
24. Zang X, Thompson RH, Al-Ahmadie HA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A.2007;104: 19458-19463.
25. Geng L, Huang D, Liu J, et al. B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol.2008;134:1021-1027.
26. Qian Y, Hong B, Shen L, Wu Z, Yao H, Zhang L. B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells. Cell Tissue Res.2013;353:139-151.
27. Zhao X, Li DC, Zhu XG, et al. B7-H3 overexpression in pancreatic cancer promotes tumor progression. Int J Mol Med.2013;31:283-291.
28. Zhao X, Zhang GB, Gan WJ, et al. Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma. Oncol Lett.2013;5:805-812.
29. Song X, Liu J, Lu Y. Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer. Oncol Rep. 2014;31:1191-1198.